Ajinomoto Co., Ltd.

Yuka Ikenoue

Masahiro Murata

Yasuhiro Tanaka

Manabu Suzuki

Tadakiyo Nakagawa

Tatsuhiro Yamada

Kohichi Fujita

Tomoyuki Tagami

Hideki Matsumoto

Toshihiko Ando

Toshihiko Yoshimura

Akira Chiba

Naoto Koyama

Ariko Kodaira

Yuji Naito

Hideaki Kihara

Yoshitomo Chujo

Katsuya Suzuki

Shunsuke Fukuda

Ryosuke Fudo

Yoko Obayashi

Yoshitomo Chujoh

Syunsuke Fukuda

The present invention provides a method of improving or treating inflammatory bowel disease through suppression of the expression of inflammatory cytokines based on the action mechanism of suppression of NF-&#x3ba;B activation by administering feruloyl serotonin to a subject in need of treatment of inflammatory bowel disease. The feruloyl serotonin of the present invention can be administered as a pharmaceutical agent or a food.

Method of treating inflammatory bowel disease

A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&#x3b1; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&#x3b1;.

Heterocyclic compounds

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Yand Yare nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Group of antitumor compounds and method for producing the same

Growing community of inventors

Kawasaki, Japan

Yuka Ikenoue